Abstract:Purpose/Objective(s) programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1 inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainty about the timing, fraction dose and total dose for PD-1 inhibitors combination with radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new pattern for R/M NPC. Materials/Methods We prospectively enrolled 42 R/M NPC patients from August 2018 to May 2021 in out institution. All the patients received concurrent PD-1 inhibitor combination with chemoradiation, and followed with maintenance of PD-1 inhibitors, and we analyzed PD-L1 expression by 22C3 kit. Objective response rate (ORR) and disease control rate (DCR) were calculated by irRECIST 1.1. CTCAE-5.0 was used to evaluate the toxicity and Kaplan-Meier method was used to analyze survival rate. Results The median age was 48 years old (range 25-81), the median follow up time was 16.5 months (range 2-62). Nine patients had recurrent disease, 33 patients had metastatic disease, and 3 patients had both recurrence and metastasis disease. The median numbers of metastatic sites were 3 (range 1-7), and the most common metastatic sites were lung and liver. All the recurrent and measurable metastatic lesions were treated with radiotherapy. 9 recurrent patients received a median radiation dose of 60Gy. The measurable metastatic lesions received a median radiation dose of 54Gy. The median cycles of cisplatin-based chemotherapy were 5. Median time of PD-1 inhibitor was 9.5 months. At 3 months after the completion of chemoradiation, ORR and DCR were 90.5% and 100% respectively. The median PFS was 18 months, with 6 and 12 months PFS rates were 90.2% and 70.7%. 1 and 2-years OS rates were 94.6% and 86.2%, and the median OS had not reached. For the PD-L1 expression, 24 patients were positive, 18 were negative. The median PFS was 20.7 and 16.5 months for positive and negative group, respectively (p=0.01). Most common G3-4 toxicities were leucopenia (45.2%), anemia (38.1%), anorexia (7.1%), and fatigue (7.1%). There was no G3-4 toxicity for pneumonia, and no G5 toxicity was observed. Conclusion This new treatment pattern of concurrent PD-1 inhibitors combination with chemoradiation shows a promising efficacy and tolerable toxicity for R/M NPC. The patients with positive PD-L1 expression had better survival outcome than negative group. Keywords: PD-1 inhibitors, concurrent, recurrent, metastatic, nasopharyngeal carcinoma, chemoradiation

Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer

Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma

A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma

Clinical Response and Biomarker Analysis of POLARIS-02 a Phase II Study of Toripalimab, a Humanized IgG4 Mab Against Programmed Death-1 (PD-1) in Patients with Metastatic Nasopharyngeal Carcinoma.

Preliminary Analysis of Concurrent Programmed Cell Death-1 Inhibitor Combination with Chemoradiation for Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: A Phase II Study

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study

Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.

Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial

Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy

A retrospective analysis of tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy plus nimotuzumab in patients with high-risk nasopharyngeal carcinoma.

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study

Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)

Four-year Overall Survival Follow-Up and Dynamic EBV Titer Analysis of Toripalimab Versus Placebo in Combination with Gemcitabine and Cisplatin As First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (r/m NPC).

Stereotactic Body Radiotherapy To Extend The Clinical Benefit Of Pd-1 Inhibitors In Recurrent/Metastatic Nasopharyngeal Carcinoma.

Abstract 4025: A phase II trial of neoadjuvant gemcitabine, cisplatin plus tislelizumab followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Clinical efficacy, safety and the biomarker analysis

Safety and Efficacy of Iparomlimab and Tuvonralimab in Combination with Gemcitabine and Cisplatin As First-Line Treatment for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Trial (DUBHE-N-302).